Shares of Vanda Pharmaceuticals Inc. (VNDA) have appreciated over the past three months, reaching new highs, driven by multiple late-stage regulatory catalysts and improving product revenue trends.The company markets three approved therapies - Fanapt, Hetlioz, and Ponvory - and has three drug candidates awaiting FDA approval for their first indications.Fanapt, an antipsychotic, is indicated for th...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.